Sascha Dublin1,2, Rod L Walker1, Shelly L Gray3, Rebecca A Hubbard4, Melissa L Anderson1, Onchee Yu1, Paul K Crane5, Eric B Larson1,5. 1. Group Health Research Institute, Seattle, Washington. 2. Department of Epidemiology, University of Washington, Seattle, Washington. 3. School of Pharmacy, University of Washington, Seattle, Washington. 4. Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. 5. Division of General Internal Medicine, Department of Medicine, University of Washington, Seattle, Washington.
Abstract
OBJECTIVES: To determine whether prescription opioid use is associated with higher dementia risk or greater cognitive decline. DESIGN: Prospective cohort study. SETTING: Group Health, an integrated healthcare delivery system. PARTICIPANTS: Community-dwelling individuals aged 65 and older without dementia with at least 10 years of Group Health enrollment at baseline (N = 3,434; median age 74). MEASUREMENTS: The Cognitive Abilities Screening Instrument (CASI) was administered every 2 years. Low scores triggered detailed evaluation, and a multidisciplinary committee assigned dementia diagnoses. From computerized pharmacy data, cumulative opioid exposure was defined as total standardized doses (TSDs) dispensed over 10 years (excluding the most recent year because of possible prodromal symptoms). For comparison, use of nonsteroidal anti-inflammatory drugs (NSAIDs), characterized similarly, was examined. Dementia risk was analyzed using Cox proportional hazards models and CASI trajectory using linear regression models and generalized estimating equations. RESULTS:Seven hundred ninety-seven participants (23%) developed dementia over a mean follow-up of 7.3 years; 637 (19%) had possible or probable Alzheimer's disease. For cumulative opioid use, the hazard ratios (HRs) for dementia were 1.06 (95% confidence interval (CI) = 0.88-1.26) for 11 to 30 TSDs, 0.88 (95% CI = 0.70-1.09) for 31 to 90 TSDs, and 1.29 (95% CI = 1.02-1.62) for 91 or more TSDs, versus 0 to 10 TSDs. A similar pattern was seen for NSAID use. Heavier opioid use was not associated with more-rapid cognitive decline. CONCLUSION: People with the heaviest opioid or NSAID use had slightly higher dementia risk than people with little or no use. These results may reflect an effect of chronic pain on cognition or residual confounding. Although opioids have other risks, little evidence of long-term cognitive harm specific to opioids was found.
RCT Entities:
OBJECTIVES: To determine whether prescription opioid use is associated with higher dementia risk or greater cognitive decline. DESIGN: Prospective cohort study. SETTING: Group Health, an integrated healthcare delivery system. PARTICIPANTS: Community-dwelling individuals aged 65 and older without dementia with at least 10 years of Group Health enrollment at baseline (N = 3,434; median age 74). MEASUREMENTS: The Cognitive Abilities Screening Instrument (CASI) was administered every 2 years. Low scores triggered detailed evaluation, and a multidisciplinary committee assigned dementia diagnoses. From computerized pharmacy data, cumulative opioid exposure was defined as total standardized doses (TSDs) dispensed over 10 years (excluding the most recent year because of possible prodromal symptoms). For comparison, use of nonsteroidal anti-inflammatory drugs (NSAIDs), characterized similarly, was examined. Dementia risk was analyzed using Cox proportional hazards models and CASI trajectory using linear regression models and generalized estimating equations. RESULTS: Seven hundred ninety-seven participants (23%) developed dementia over a mean follow-up of 7.3 years; 637 (19%) had possible or probable Alzheimer's disease. For cumulative opioid use, the hazard ratios (HRs) for dementia were 1.06 (95% confidence interval (CI) = 0.88-1.26) for 11 to 30 TSDs, 0.88 (95% CI = 0.70-1.09) for 31 to 90 TSDs, and 1.29 (95% CI = 1.02-1.62) for 91 or more TSDs, versus 0 to 10 TSDs. A similar pattern was seen for NSAID use. Heavier opioid use was not associated with more-rapid cognitive decline. CONCLUSION:People with the heaviest opioid or NSAID use had slightly higher dementia risk than people with little or no use. These results may reflect an effect of chronic pain on cognition or residual confounding. Although opioids have other risks, little evidence of long-term cognitive harm specific to opioids was found.
Authors: Walter A Kukull; Roger Higdon; James D Bowen; Wayne C McCormick; Linda Teri; Gerard D Schellenberg; Gerald van Belle; Lance Jolley; Eric B Larson Journal: Arch Neurol Date: 2002-11
Authors: Sascha Dublin; Rod L Walker; Michael L Jackson; Jennifer C Nelson; Noel S Weiss; Michael Von Korff; Lisa A Jackson Journal: J Am Geriatr Soc Date: 2011-09-13 Impact factor: 5.562
Authors: E L Teng; K Hasegawa; A Homma; Y Imai; E Larson; A Graves; K Sugimoto; T Yamaguchi; H Sasaki; D Chiu Journal: Int Psychogeriatr Date: 1994 Impact factor: 3.878
Authors: Anil Kuchinad; Petra Schweinhardt; David A Seminowicz; Patrick B Wood; Boris A Chizh; M Catherine Bushnell Journal: J Neurosci Date: 2007-04-11 Impact factor: 6.167
Authors: A Vania Apkarian; Yamaya Sosa; Sreepadma Sonty; Robert M Levy; R Norman Harden; Todd B Parrish; Darren R Gitelman Journal: J Neurosci Date: 2004-11-17 Impact factor: 6.167
Authors: Shelly L Gray; Rod L Walker; Sascha Dublin; Onchee Yu; Erin J Aiello Bowles; Melissa L Anderson; Paul K Crane; Eric B Larson Journal: J Am Geriatr Soc Date: 2017-11-14 Impact factor: 5.562
Authors: Margaret E Flanagan; Eric B Larson; Rod L Walker; C Dirk Keene; Nadia Postupna; Brenna Cholerton; Joshua A Sonnen; Sascha Dublin; Paul K Crane; Thomas J Montine Journal: J Alzheimers Dis Date: 2018 Impact factor: 4.472
Authors: Elizabeth L Whitlock; L Grisell Diaz-Ramirez; M Maria Glymour; W John Boscardin; Kenneth E Covinsky; Alexander K Smith Journal: JAMA Intern Med Date: 2017-08-01 Impact factor: 21.873
Authors: Ali Ezzati; Cuiling Wang; Mindy J Katz; Carol A Derby; Andrea R Zammit; Molly E Zimmerman; Jelena M Pavlovic; Martin J Sliwinski; Richard B Lipton Journal: Curr Alzheimer Res Date: 2019 Impact factor: 3.498
Authors: Sascha Dublin; Rod L Walker; Shelly L Gray; Rebecca A Hubbard; Melissa L Anderson; Onchee Yu; Thomas J Montine; Paul K Crane; Josh A Sonnen; Eric B Larson Journal: J Alzheimers Dis Date: 2017 Impact factor: 4.472